Characterization of reverse genetics-derived cold-adapted master donor virus a/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 722-731

  Isakova Sivak, Irina ^a,b   Chen, Li Mei ^a   Bourgeois, Melissa ^a,d   Matsuoka, Yumiko ^a,e   Voeten, J Theo M ^c,d   Heldens, Jacco G M ^c,d   Van Den Bosch, Han ^c,f   Klimov, Alexander ^a   Rudenko, Larisa ^b   Cox, Nancy J ^a   Donis, Ruben O ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c Nobilon International BV   (Netherlands)

^d MERCK ANIMAL HEALTH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f ATHENA INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; IMMUNOGLOBULIN A; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; NA PROTEIN, INFLUENZA A VIRUS; RECOMBINANT VACCINE; SIALIDASE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CLADISTICS; COLD ADAPTED MASTER DONOR VIRUS; CONTROLLED STUDY; FEMALE; HA GENE; HEMAGGLUTINATION INHIBITION TEST; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFLUENZA A (H2N2); INFLUENZA A (H5N1); INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H5N1; LUNG; MDCK CELL LINE; MOUSE; NA GENE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; REVERSE GENETICS; VACCINE PRODUCTION; VIRAL GENETICS; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ANIMAL STRUCTURES; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENETIC REASSORTMENT; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SURVIVAL; VACCINATION; VIROLOGY; VIRULENCE;

ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; REVERSE GENETICS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRULENCE;

EID: 84899759275     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00819-13     Document Type: Article

References (53)

1. Peiris JS, de Jong MD, Guan Y. 2007. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 20:243-267. http://dx.doi.org/10. 1128/CMR.00037-06. (Pubitemid 46709304)
2. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273. http://dx.doi.org/10.1056/NEJMra0707279.
3. WHO. 2014. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/human-animal-interface/EN-GIP- 20131210CumulativeNumberH5N1cases.pdf?ua=1. Accessed January 2014.
4. OIE (World Organization for Animal Health). 2008. Manual of diagnostic tests and vaccines for terrestrial animals, 6th ed, vol 1, p 323-333. OIE (World Organization for Animal Health), Paris, France.
5. Sims LD, Domenech J, Benigno C, Kahn S, Kamata A, Lubroth J, Martin V, Roeder P. 2005. Origin and evolution of highly pathogenic H5N1 avian influenza in Asia. Vet. Rec 157(6):159-164. (Pubitemid 41167136)
6. OIE (World Organization for Animal Health). 6 June 2012. Outbreaks of highly pathogenic avian influenza (subtype H5N1) in poultry. OIE (World Organization for Animal Health), Paris, France. http://www.oie.int/fileadmin/ Home/eng/Animal-Health-in-the-World/docs/pdf/graph-avian-influenza/ graphs-HPAI-06-06-2012.pdf.
7. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. 2010. High genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 84:10918-10922. http://dx.doi.org/10.1128/JVI. 01140-10.
8. Leroux-Roels I, Leroux-Roels G. 2009. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8:401-423. http://dx.doi.org/10.1586/erv.09.15.
9. Rudenko L, Desheva J, Korovkin S, Mironov A, Rekstin A, Grigorieva E, Donina S, Gambaryan A, Katlinsky A. 2008. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respir. Viruses 2:203-209. http://dx.doi.org/10.1111/j.1750- 2659.2008.00064.x.
10. Svindland SC, Jul-Larsen A, Pathirana R, Andersen S, Madhun A, Montomoli E, Jabbal-Gill I, Cox RJ. 2012. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respir. Viruses 6:90-100. http://dx.doi.org/10.1111/j.1750-2659.2011. 00271.x.
11. Landry N, Ward BJ, Trepanier S, Montomoli E, Dargis M, Lapini G, Vezina LP. 2010. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559. http://dx.doi.org/10. 1371/journal.pone.0015559.
12. Yang P, Duan Y, Zhang P, Li Z, Wang C, Dong M, Tang C, Xing L, Gu H, Zhao Z, Liu X, Zhang S, Wang X. 2012. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination. PLoS One 7:e30252. http://dx.doi.org/10.1371/journal. pone.0030252.
13. Vesikari T, Forsten A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. 2012. Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30:1388-1396. http://dx.doi.org/10.1016/j.vaccine.2011.12.009.
14. WHO. 2012. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines. WHO, Geneva, Switzerland. http://www.who.int/influenza/ vaccines/virus/201202-h5-h9-vaccinevirusupdate.pdf.
15. Cox RJ, Brokstad KA, Ogra P. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15. http://dx.doi.org/10.1111/j.0300-9475.2004.01382.x. (Pubitemid 38186834)
16. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, Szretter K, Cox NJ, Rudenko LG, Klimov A, Katz JM. 2006. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593. http://dx.doi.org/10.1016/j.vaccine.2006.05.039. (Pubitemid 46107146)
17. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. 2004. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3:643-654. http://dx.doi.org/10.1586/14760584.3.6.643. (Pubitemid 39576751)
18. Tamura S, Tanimoto T, Kurata T. 2005. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58:195-207. (Pubitemid 41460922)
19. Jang YH, Byun YH, Lee YJ, Lee YH, Lee KH, Seong BL. 2012. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits crossreactive immune responses against seasonal and H5 influenza A viruses. J. Virol. 86:5953-5958. http://dx.doi.org/10.1128/JVI.07149-11.
20. Lau YF, Wright AR, Subbarao K. 2012. The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection. J. Virol. 86:5089-5098. http://dx.doi.org/10.1128/JVI.07205-11.
21. Rudenko LG, Lonskaya NI, Klimov AI, Vasilieva RI, Ramirez A. 1996. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull. World Health Organ. 74:77-84.
22. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW. 2007. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J. Immunol. 178:1030-1038. (Pubitemid 46095176)
23. Quan FS, Compans RW, Nguyen HH, Kang SM. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82:1350-1359. http://dx.doi.org/10.1128/JVI.01615-07.
24. Cheng X, Eisenbraun M, Xu Q, Zhou H, Kulkarni D, Subbarao K, Kemble G, Jin H. 2009. H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines. PLoS One 4:e4436. http://dx.doi.org/10. 1371/journal.pone.0004436.
25. Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, et al. 1993. Efficacy of live attenuated and inactivated influenza vaccines in school-children and their unvaccinated contacts in Novgorod, Russia. J. Infect. Dis. 168:881-887. http://dx.doi.org/10.1093/infdis/168.4.881. (Pubitemid 23282559)
26. Klimov AI, Egorov AY, Gushchina MI, Medvedeva TE, Gamble WC, Rudenko LG, Alexandrova GI, Cox NJ. 1995. Genetic stability of cold-adapted A/Leningrad/134/47/57 (H2N2) influenza virus: sequence analysis of live cold-adapted reassortant vaccine strains before and after replication in children. J. Gen. Virol. 76:1521-1525. http://dx.doi.org/10.1099/0022-1317-76-6- 1521.
27. Rudenko LG, Ramirez A, Barro M, Gushchina MI, Armanda RE, Ermachenko TA, Romanova IR, Grigor'eva EP, Aleksandrova GI, Lonskaia NI. 1991. The inoculation properties of live recombinant influenza vaccine types A and B used separately and jointly in children 3 to 14. Vopr. Virusol. 36:472-474. (In Russian.)
28. Aleksandrova GI, Medvedeva TE, Polezhaev FI, Garmashova LM, Budilovskii GN. 1986. Reactogenicity, genetic stability and effectiveness of a live recombinant influenza vaccine for children designed on the base of a cold-adapted attenuation donor A/Leningrad/134/47/57. Vopr. Virusol. 31:411-414. (In Russian.)
29. Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, Stanzani V, Lapini G. 2012. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev. Vaccines 11:587-594. http://dx.doi.org/10.1586/erv.12.24.
30. Perdue ML, Arnold F, Li S, Donabedian A, Cioce V, Warf T, Huebner R. 2011. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 10:1183-1194. http://dx.doi.org/10.1586/erv.11.82.
31. Liu K, Yao Z, Zhang L, Li J, Xing L, Wang X. 2012. MDCK cell-cultured influenza virus vaccine protects mice from lethal challenge with different influenza viruses. Appl. Microbiol. Biotechnol. 94:1173-1179. http://dx.doi.org/10.1007/s00253-011-3860-8.
32. Aleksandrova GI, Mikutskaia BA, Pleshanova RA, Panova NG, Smorodintsev AA. 1965. The reactive and immunogenic properties and epidemiological effectiveness of further attenuated influenza virus vaccinal strains (observed in preschool children). Vopr. Virusol. 10:67-73. (In Russian.)
33. WHO. 2009. Availability of a new recombinant H5N1 vaccine virus. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/vaccines/ virus/H5N1virus26May/en/index.html.
34. WHO. 2005. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11:1515-1521. http://dx.doi.org/10.3201/eid1110.050644.
35. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113. http://dx.doi.org/10.1073/pnas. 100133697. (Pubitemid 30367531)
36. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N, Matsuoka Y. 2003. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305:192-200. http://dx.doi.org/10.1006/viro.2002. 1742. (Pubitemid 36062823)
37. Isakova-Sivak I, Chen LM, Matsuoka Y, Voeten JT, Kiseleva I, Heldens JG, den Bosch H, Klimov A, Rudenko L, Cox NJ, Donis RO. 2011. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 412:297-305. http://dx.doi.org/10.1016/j.virol.2011.01.004.
38. WHO. 2002. WHO manual on animal influenza diagnosis and surveillance. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/ 2002/who-cds-csr-ncs-2002.5.pdf.
39. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. 2004. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 103:91-95. http://dx.doi.org/10.1016/j.virusres.2004.02.019. (Pubitemid 38649066)
40. Balish AL, Davis CT, Saad MD, El-Sayed N, Esmat H, Tjaden JA, Earhart KC, Ahmed LE, Abd El-Halem M, Ali AH, Nassif SA, El-Ebiary EA, Taha M, Aly MM, Arafa A, O'Neill E, Xiyan X, Cox NJ, Donis RO, Klimov AI. 2010. Antigenic and genetic diversity of highly pathogenic avian influenza A (H5N1) viruses isolated in Egypt. Avian Dis. 54:329-334. http://dx.doi.org/10.1637/8903-042909-Reg.1.
41. Matsuoka Y, Lamirande EW, Subbarao K. 2009. The mouse model for influenza. Curr. Protoc. Microbiol. Chapter 15:Unit 15G.3. http://dx.doi.org/10. 1002/9780471729259.mc15g03s13.
42. Voeten JT, Kiseleva IV, Glansbeek HL, Basten SM, Drieszen-van der Cruijsen SK, Rudenko LG, van den Bosch H, Heldens JG. 2010. Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model. Arch. Virol. 155:1391-1399. http://dx.doi.org/10.1007/s00705- 010-0719-8.
43. Committee for Medicinal Products for Human Use. 2008. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. EMEA/CPMP/VEG/4717/03-Rev.1. Committee for Medicinal Products for Human Use, European Medicines Agency, London, United Kingdom.
44. Suguitan AL, Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360. http://dx.doi.org/10.1371/journal.pmed.0030360.
45. Wareing MD, Watson JM, Brooks MJ, Tannock GA. 2001. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza A vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J. Med. Virol. 65:171-177. http://dx.doi.org/10.1002/jmv.2017.
46. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI. 2006. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24:6859-6866. http://dx.doi.org/10.1016/j.vaccine.2006.06.023. (Pubitemid 46107188)
47. Ge S, Wang Z. 2011. An overview of influenza A virus receptors. Crit. Rev. Microbiol. 37:157-165. http://dx.doi.org/10.3109/1040841X.2010.536523.
48. Jackson S, Van Hoeven N, Chen LM, Maines TR, Cox NJ, Katz JM, Donis RO. 2009. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. J. Virol. 83:8131-8140. http://dx.doi.org/10.1128/JVI.00534-09.
49. Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO. 2008. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 4:e1000072. http://dx.doi.org/10.1371/ journal.ppat.1000072.
50. Clements ML, Murphy BR. 1986. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol. 23:66-72. (Pubitemid 16186972)
51. Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, Chen GL, Lamirande EW, Jin H, Coelingh KL, Murphy BR, Kemble G, Subbarao K. 2009. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 27:3744-3753. http://dx.doi.org/10. 1016/j.vaccine.2009.03.082.
52. Karron RA, Talaat K, Luke C, Callahan K, Thumar B, Dilorenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K, Chen G, Lamirande E, Coelingh K, Jin H, Murphy BR, Kemble G, Subbarao K. 2009. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27:4953-4960. http://dx.doi.org/10.1016/j.vaccine.2009.05.099.
53. Gustin KM, Maines TR, Belser JA, van Hoeven N, Lu X, Dong L, Isakova-Sivak I, Chen LM, Voeten JT, Heldens JG, van den Bosch H, Cox NJ, Tumpey TM, Klimov AI, Rudenko L, Donis RO, Katz JM. 2011. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J. Infect. Dis. 204:1491-1499. http://dx.doi.org/10.1093/infdis/jir596.